Resistance in HIV+ in North and South

• Register: ClinicalTrials.gov
• Last refreshed on: 3 August 2015
• Main ID: NCT02507921
• Date of registration: 16/06/2015
• Prospective Registration: No
• Primary sponsor: Infectious Diseases Institute
• Public title: Resistance in HIV+ in North and South RHINOS
• Scientific title: Comparing Type and Prevalence of HIV Drug Resistance in Treatment Experienced and naïve HIV-infected Adults in Uganda and Switzerland
• Date of first enrolment: May 2015
• Target sample size: 2750
• Recruitment status: Recruiting
• URL: https://clinicaltrials.gov/show/NCT02507921
• Study type: Observational [Patient Registry]
• Study design: Observational Model: Cohort, Time Perspective: Cross-Sectional
• Phase: N/A

Countries of recruitment

Uganda

Contacts

• Name: Amrei von Braun, MD

• Name: Amrei von Braun, MD

Key inclusion & exclusion criteria

Inclusion Criteria:

- Evidence of a personally signed and dated informed consent document indicating that
the participant (or a legal representative) has been informed of all pertinent
aspects of the study.

- Participants who are willing and able to comply with scheduled visits, laboratory
tests, and other study procedures.

- Age = 18 years

- ART naïve OR on stable ART regimen = 6 months (first- or second-line)

Exclusion Criteria:

There are no exclusion criteria.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

HIV Drug Resistance

Primary Outcome(s)

HIV drug resistance in treatment-naive patients [Time Frame: up to 12hrs]

HIV drug resistance in treatment-experienced patients [Time Frame: up to 12hrs]

Secondary Outcome(s)

Viroligical failure [Time Frame: up to 12hrs]

Secondary ID(s)

ST/0112/15

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

University of Zurich